Drug Trial Radar · NCT07602127
Safety and Efficacy Study of Novel Gene Therapy AGX-08 for Geographic Atrophy
Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Dec 30, 2028
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- Augelux TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 22, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is AGX-08's safety, tolerability, and efficacy in Geographic Atrophy first-in-human study. This trial is meant to evaluate the safety and efficacy of AGX-08 in Geographic Atrophy patients. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.
Conditions
- Geographic Atrophy
Interventions
AGX-08-LDrug
rAAV2.AG-eNCRV intravitreal injection of low dose
AGX-08-HDrug
rAAV2.AG-eNCRV intravitreal injection of high dose
AGX-08-SProcedure
sham intravitreal injection of AGX-08 (not actual injection)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events,adverse events, serious adverse events and dose-limiting toxicitiesTime frame: baseline to Week 52
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.